Vibalogics set for live biological filling boost
The CDMO has expanded its capabilities with a new automatic vial filling line to meet increased demand.
Germany-based Vibalogics has expanded its capabilities with a new automatic vial filling line to meet increased demand from biotechnology companies for its specialist live biological manufacturing services for human and veterinary vaccines, gene therapeutics and live virus vectors.
The investment by the contract development and manufacturing organisation (CDMO) extends its aseptic fill and finish capability by around 300%, reinforcing its ability to support early-phase biologic supply needs for Phase I and II clinical trials.
Operating from a multi-product BSL-2 facility in northern Germany, family-owned Vibalogics specialises in the handling and manufacture of viruses and live bacterial products for therapeutic and prophylactic applications.
Its new Bosch ARF 1020 filling machine will enable Vibalogics to fill 7,200 vials per hour with a maximum validated batch size for automatic liquid filling of 30,000 vials. This is complemented by a Seidenader visual inspection station and automatic labelling machine to handle the larger batch sizes.
Commenting on the investment, Dr. Stefan Beyer, managing director at Vibalogics said: “Our contract services business specialises in the aseptic processing of live biological products. The new filling line provides state of the art technology to meet the growing demand for this service from clients across the world.
“The idea behind the investment was to establish more manufacturing capacity to be prepared for outbreaks of highly devastating infectious diseases like the Ebola virus case in 2014/15. We also wanted to ensure customers from small biotechs and well-established pharma could benefit from greater quality, scale and faster processing times, which can be critical with the types of products we handle.
“As the biopharma sector continues to strengthen, we are committed to investing in the technology and equipment needed to meet our customers’ requirements.”
From its facility in Cuxhaven, Germany, Vibalogics provides process development and GMP manufacturing services, with a particular focus on aseptic processing of live viruses and live bacteria.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115850. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance